Novus Biologicals introduces new LDHA Antibody

Novus Biologicals recently introduced an antibody to Lactate dehydrogenase A (LDHA).  LDHA is involved in the final step of anaerobic glycoysis and catalyzes the conversion of L-lactate and NAD to pryruvate and NADH. Novus' new rabbit polyclonal anti-LDHA antibody (catalog # NBP1-48336) was made within residues 300-375 of the human LDHA protein.

Novus' new LDHA antibody has been positively validated for use in immunocytochemistry and Western blot analysis.  By Western blot, this LDH-A antibody was tested on HeLa whole cell lysate (NB800-PC1), NIH/3T3 lysate (NB800-PC8) and A549 cell lysate, all of which displayed a clear and strong band at ~36kDa.

Lactate dehydrogenase (LDH) is an ubiquitous enzyme involved in the interconversion of the pyruvate and NADH to lactate and NAD+.  In mammals, three types of LDH subunits are encoded by the genes LDHA, LDHB, and LDHC, forming various terameric isoenzymes.  While LDHA is predominantly expressed in muscle tissue, it is hormonally regulated in rodents and overexpressed during mammary gland tumorigenesis.

Novus provides other Lactate Dehydrogenase antibodies, proteins and RNAi which can be found here. LDHA -related products are also available from Novus, including: LDHB, LDHC and c-Myc.


For more information on this new LDHA antibody or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at

Release Date: 
Thursday, October 14, 2010 - 06:00